Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. We show 48 historical shares outstanding datapoints in our AGEN shares outstanding history coverage, used to compute AGEN market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing AGEN market cap history over the course of time is important for investors
interested in comparing AGEN's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of AGEN versus a peer is one thing; comparing
AGEN market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like AGEN can fluctuate over the course of history.
With this page we aim to empower investors researching AGEN by allowing them to research the AGEN market cap history. |
Free AGEN Email Alerts:
Video: The Importance of Market Cap
